Sign up for free insights newsletter
GD

Galderma Group AG/ADR

GDERFUnited States

Need professional-grade analysis? Visit stockanalysis.com

$204.70
+2.22%
End of day
Market Cap

$48.67B

P/E Ratio

79.96

Employees

7,676

Dividend Yield

0.21%

Price Chart

Risk-Adjusted Performance

Ratio1W1M3M6M1Y5YScore
Sortino36.707.271.513.666.30
Calmar54.663.235.7413.72
Sharpe20.564.250.881.993.54
Omega1.981.541.261.601.51
Martin9.0719.0914.64
Ulcer3.253.275.564.704.63

Galderma Group AG/ADR (GDERF) Price Performance

Galderma Group AG/ADR (GDERF) trades on United States in USD. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at $204.70, up 2.22% from the previous close.

Over the past year, GDERF has traded between a low of $107.92 and a high of $208.90. The stock has gained 89.7% over this period. It is currently 89.7% above its 52-week low.

Galderma Group AG/ADR has a market capitalization of $48.67B, with a price-to-earnings ratio of 79.96 and a dividend yield of 0.21%.

About Galderma Group AG/ADR

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.

Compare Galderma Group AG/ADR

Side-by-side comparison against top Healthcare peers.

Company Info

Exchange
United States
Currency
USD

Financial Metrics

Revenue (TTM)
$5.24B
EBITDA
$1.13B
Profit Margin
11.70%
EPS (TTM)
2.59
Book Value
34.74

Technical Indicators

52 Week High
$213.50
52 Week Low
$107.92
50 Day MA
$194.26
200 Day MA
$181.32
Beta
-0.10

Valuation

Trailing P/E
79.96
Forward P/E
46.51
Price/Sales
9.29
Price/Book
5.96
Enterprise Value
$49.36B